Related Experiment Video
Updated: Sep 27, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Prophylaxis and treatment of recurrent hepatitis B after liver transplantation
Chung-Mau Lo1, Sheung-Tat Fan, Chi-Leung Liu
1Centre for the Study of Liver Disease and the Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China. chungmlo@hkucc.hku.hk.
Abstract:
Chronic hepatitis B virus (HBV) infection is the leading cause of end-stage liver disease in Asia. The results of liver transplantation in these patients have significantly improved to a level comparable to those of other recipients as a result of the rapid evolution in the strategies of prevention and treatment of recurrent hepatitis B over the past decade. Hepatitis B immune globulin (HBIG) and lamivudine, either alone or in combination, are effective in preventing reinfection, but the most cost-effective dosing regimen with optimum efficacy without the prohibitive cost remains to be determined, an issue that is particularly relevant to liver transplant centers with serious financial constraints in Asia. The idea of active immunization is attractive, but the results have been conflicting to date. The newer nucleoside analogs appear most promising, and a combination of two or more antiviral agents is likely to represent the future strategy of choice in the prophylaxis and treatment of recurrent hepatitis B after liver transplantation.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management